Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy

Author(s): Marco L. Lolli, Stefano Sainas, Agnese C. Pippione, Marta Giorgis, Donatella Boschi, Franco Dosio*

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 13 , Issue 1 , 2018

Become EABM
Become Reviewer
Call for Editor


Background: Human dihydroorotate dehydrogenase (hDHODH, EC, a flavindependent mitochondrial enzyme involved in de novo pyrimidine biosynthesis, is a validated therapeutic target for the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. However, human DHODH inhibitors have also been investigated as treatment for cancer, parasite infections (i.e. malaria) and viruses as well as in the agrochemicals industry.

Objective: An overview of current knowledge of hDHODH inhibitors and their potential uses in diseases where hDHODH is involved.

Method: This review focuses on recent advances in the development and application of hDHODH inhibitors, specifically covering the patent field, starting from a brief description of enzyme topography and of the strategies usually followed in designing its selective inhibitors.

Results: The most important and well-described novelty is the fact that the discovery, in the autumn of 2016, that hDHODH inhibitors are able to induce in vivo myeloid differentiation has led to the possibility of developing novel hDHODH based treatments for Acute Myelogenous Leukemia (AML).

Conclusion: The review will describe a variety of specific inhibitor classes and conclude on recent and future therapeutic perspectives for this target.

Keywords: Autoimmune diseases, brequinar, cancer, dihydroorotate dehydrogenase (DHODH), inhibitors, leflunomide, leukemia, melanoma.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [86 - 105]
Pages: 20
DOI: 10.2174/1574892812666171108124218

Article Metrics

PDF: 240
HTML: 63
EPUB: 13
PRC: 4